The recent RAF inhibitor trial with PLX4032/RG7204 in late-stage mutant B-RAF melanoma patients has been lauded as a success story for personalized cancer therapy since short-term clinical responses were observed in the majority of patients. However, initial responses were followed by subsequent tumor re-growth, and a subset of patients showed intrinsic resistance. Bi-directional translational efforts are now essential to determine the mechanisms underlying acquired/secondary and intrinsic resistance to RAF inhibitors.
Recommended CitationAplin, A E; Kaplan, Fred M; and Shao, Yongping, "Mechanisms of resistance to RAF inhibitors in melanoma." (2011). Department of Cancer Biology Faculty Papers. Paper 50.